Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Pelvic inflammatory disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Pelvic inflammatory disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Vulvar intraepithelial neoplasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Vulvar intraepithelial neoplasia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
8 min read
Moberg Pharma Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Moberg Pharma BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Latest Hotspot
10 min read
Vulvar lichen sclerosus Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Vulvar lichen sclerosus strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Lichen planus vulvovaginal Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Lichen planus vulvovaginal strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Vaginal agenesis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Vaginal agenesis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Vaginal atrophy Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Vaginal atrophy indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Genitourinary syndrome of menopause Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Genitourinary syndrome of menopause strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Provoked vestibulodynia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Provoked vestibulodynia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Premenstrual syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Premenstrual syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Sheehan syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Sheehan syndrome indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Hyperprolactinemia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Hyperprolactinemia indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.